Hikma Pharmaceuticals Plc

As of June 30, 2026, Hikma Pharmaceuticals Plc carries a market capitalization of 3.78B, placing it among publicly traded companies globally. Its enterprise value stands at 5.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hikma Pharmaceuticals Plc's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2026, Hikma Pharmaceuticals Plc has 211.28M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hikma Pharmaceuticals Plc maintains a current ratio of 1.98, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on August 12, 2026, Hikma Pharmaceuticals Plc's stock has declined approximately 8.70% over the past 52 weeks. The 50-day moving average sits at 17.96, while the 200-day moving average is 17.26.

As of June 30, 2026, Hikma Pharmaceuticals Plc holds 252.96M in cash and equivalents against 1.71B in total debt, resulting in a net debt position of 1.41B. Total book value stands at 2.21B, with working capital of 1.19B providing operational flexibility.